ADS-5102, 274 mg

DRUG2 trials

Sponsors

Adamas Pharmaceuticals, Inc.

Conditions

Multiple SclerosisWalking Impairment

Phase 3

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

CompletedNCT03436199

Adamas Pharmaceuticals, Inc.Multiple Sclerosis, Walking Impairment

Start: 2018-03-29End: 2019-12-10Updated: 2021-12-21

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

CompletedNCT03567057

Adamas Pharmaceuticals, Inc.Multiple Sclerosis, Walking Impairment

Start: 2018-07-18End: 2021-04-18Updated: 2022-01-18